DLL4 and neoplasm: Demcizumab (OMP-21M18) is a humanized anti-DLL4 (delta-like ligand 4) antibody that inhibits the Notch pathway and CSC activity through the inhibition of tumor growth and reduction in tumor-initiating cell frequency [134,135,136].